therapy
-
Investigational oral MS therapy significantly reduced relapse rate
Findings from two-year phase 3 trial published in New England Journal of Medicine.
therapy | 06 October 2011
-
Abbott receives FDA approval for ALK gene test for lung cancer therapy selection
Abbott announced it has received approval from the US Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC). The new…
therapy | 27 August 2011
-
CEL-SCI receives key Chinese patent for its investigational cancer therapy Multikine
CEL-SCI Corporation announced that the Chinese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine (Leukocyte Interleukin, Injection). The patent, Chinese patent number ZL200480025403.6, is titled, “A M…
therapy | 18 August 2011
-
Fixed dose combination therapy for high blood pressure approved in Singapore
• Study shows fixed dose combination therapy is effective in the treatment of high blood pressure.
therapy | 26 July 2011
-
Abbott submits molecular test for lung cancer therapy
Abbott announced it filed premarket approval applications to the US FDA and the Japanese Ministry of Health, Labour, and Welfare for a new molecular diagnostic test designed to detect abnormal gene rearrangements in non-small-cell lung cancer (NSCLC)…
therapy | 23 May 2011
-
Long term oral therapy for endometriosis launched in Singapore
Women with endometriosis were given fresh hope with the launch of Visanne, said to be the world's first and only long term oral therapy proven to reduce endometriosis lesion and pain. Speaking at a media conference, Associate Professor Bernard Ch…
therapy | 29 March 2011
-
Can Pfizer rescue hormonal replacement therapy?
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence …
therapy | 20 January 2011
-
Opportunities in testosterone replacement therapy
Despite growing at a compound annual growth rate of 24 percent over the last five years, the testosterone replacement therapy market is severely underdeveloped. Datamonitor, said that this suggests there are great opportunities for pharmaceutical co…
therapy | 01 January 2011
-
Addressing multiple disease targets with single protein therapy
Selexis entered into strategic agreement with Zyngenia under which Selexis will utilize its' SURE cell line development platform to generate production cell lines for Zyngenia’s lead Zybody therapeutic programs. â€We are excited to support Zy…
therapy | 03 December 2010
-
Market development key for testosterone replacement therapy
Despite growing at a compound annual growth rate of more than 24 percent over the last five years, the testosterone replacement therapy market is severely underdeveloped. Datamonitor , an independent market analyst, said that this suggests there are …
therapy | 23 November 2010
